< Back to latest news & events

Event

HGF Complete webinar: comparison of registered and unregistered design rights procedures before the EUIPO and UKIPO

March 2022

Event date: 19th May 2022

HGF is hosting a series of HGF Complete webinars this Spring.

Our expert speakers will discuss trade marks and designs in the EU and the UK. We will compare and contrast the EUIPO and UKIPO and share our views on Benelux IP Office and German IP Office practices.

Comparison of registered and unregistered design rights procedures before the EUIPO and UKIPO

A comparison of the registered and unregistered rights available for the protection of designs in the United Kingdom, Benelux and Germany. We will compare and contrast the rights which are available to design owners in those states and the EUIPO. What is the evidential burden in proving such rights and practical tips on enforcing them? We will also have a discussion of how unregistered design rights can be established in the EU and whether first disclosure is needed in the EU for such rights to be established.

Speakers

Alexander Hagen – Partner & Trade Mark Attorney

Pieter de Ruijter – Partner & Trade Mark Attorney

Jan Robert Naefe – Partner & Patent Attorney

Alastair Blake – Senior Patent Attorney

Watch the webinar below:

About HGF Complete

HGF Complete provides a ‘complete’ European trade mark and design service. Using HGF in the EU and UK means:

  • Teamwork: one team with common practices being able to advise you across borders
  • Clarity: we can advise on filing, strategy and enforcement matters with clarity not treating each state in isolation
  • Efficiency: we can offer you cost effective solutions for your EU & UK trade mark and design filings

Other webinars in this series

Trade mark application procedures before the EUIPO and UKIPO

Trade mark opposition and invalidity proceedings

Unregistered trade mark rights in the EU and UK

Latest updates

The FoodTech Series #1 | Multi-parameter claims, examples outside the scope of the claims: when improvement occurs and evidence becomes easier to demonstrate

            The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they ruled on an opposition …

Read article

A New Era for AI Patents in the UK: Supreme Court Aligns with the EPO

The UK Supreme Court has handed down its long-awaited judgment in Emotional Perception AI Limited (EPAI) vs Comptroller General of Patents, a decision which serves to significantly change the way …

Read article
Event - 23rd - 25th March 2026

HGF are Gold Sponsors of IPBC Europe 2026

HGF are proud sponsors of IPBC Europe 2026, taking place from 23-25 March 2026 at the Pullman Paris Montparnasse. Bringing together patent pioneers, in-house leaders and private practice specialists, IPBC …

Event details
Event - 8th - 11th February 2026

AUTM Meeting 2026

We are attending the AUTM Annual Meeting from 8–11 February, a flagship event bringing together technology transfer professionals from across the globe. AUTM connects innovators, universities, and industry leaders to …

Event details

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article